This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medicago Signs $15 Million Non-Dilutive Loan Agreement With A Major Pharmaceutical Partner

Continuing discussion towards further cooperation -

QUEBEC CITY, Jan. 17, 2013 /PRNewswire/ -  Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the execution of  $15,000,000 loan agreement with a major Pharmaceutical company.  The principal of the loan is repayable on January 14, 2014 but can be extended by Medicago at its option until January 14, 2016 and will bear an interest rate of not more than 10% per year. Interest on this loan will be paid quarterly. 

Medicago and its partner are continuing discussions to finalize a licensing agreement which may also include co-promotion rights of Medicago vaccines in certain markets and, if successfully concluded will result in the principal of the loan being applied as upfront payments upon the execution of the licensing agreement. In such an event, Medicago will not be required to pay interest on the loan. Whilst Medicago and its Pharma partner are pursuing discussions together under a term sheet, there can be no assurance that any additional transactions will be successfully concluded between Medicago and its partner.

"This additional investment by a major partner in our company clearly validates our rapid plant-based VLP vaccine technology given their scientific and commercial leadership in vaccines," said Andy Sheldon, President and CEO of Medicago. "This significant agreement provides a non-dilutive infusion of cash for the continued development and commercialization of our vaccines."

Medicago's pipeline includes:
  • The initiation of a U.S. Phase IIa clinical trial for a quadrivalent seasonal flu vaccine with interim data expected in summer of 2013;
  • Phase I clinical trial for an H5N1 VLP vaccine with a new adjuvant that is ongoing in partnership with the Infectious Disease Research Institute (IDRI).  Interim data are expected in the first quarter of 2013;
  • New clinical trial of the H5N1 VLP vaccine designed to determine the lowest possible dose by two different administration routes (IM and ID) and combining the vaccine with a GLA adjuvant is planned to start in spring of 2013, with interim data expected in summer of 2013;
  • GMP process development and a GLP toxicology study for a rabies vaccine are ongoing;
  • Medicago is also working with Mitsubishi Tanabe Pharma under a strategic alliance to develop a vaccine for rotavirus and at least two additional vaccine candidates;
  • In addition to vaccines, Medicago is conducting research and development in the area of biosimilar products.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,866.17 +146.25 0.83%
S&P 500 2,095.42 +15.01 0.72%
NASDAQ 5,136.63 +27.9640 0.55%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs